BIOCHAPERONE^® GLARGINE GLP-1 

BIOCHAPERONE^® GLARGINE GLP-1: a simple intensification option over basal insulin

Basal insulin remains an essential treatment for patients with type 2 diabetes who do not reach glycemic targets on oral antidiabetic agents. However, by some estimates, up to 50% of people with diabetes who use basal insulin as their only injectable treatment do not reach their glycemic target¹.

To address the need for intensification of treatment from basal insulin alone or GLP-1 alone, Adocia initiated a preclinical BioChaperone program in the preclinical stage, combining basal insulin (insulin glargine) with GLP-1 receptor agonists (“GLP1”, eg liraglutide). This program takes advantage of Adocia’s expertise in the solubilization of insulin glargine at physiological pH.

¹ Sanofi, Corporate presentation Q3 2015